{
    "id": 29253,
    "fullName": "EGFR G796R",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR G796R lies within the protein kinase domain of the Egfr protein (UniProt.org). G796R has been demonstrated to occur as a secondary drug resistance mutation (PMID: 29857056), but has not been biochemically characterized and therefore, it's effect on Egfr protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "G796R",
    "createDate": "01/28/2019",
    "updateDate": "10/06/2019",
    "referenceTranscriptCoordinates": {
        "id": 177982,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181395G>C",
        "cDna": "c.2386G>C",
        "protein": "p.G796R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15780,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31214,
                "profileName": "EGFR T790M EGFR G796R EGFR L858R"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15788,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31214,
                "profileName": "EGFR T790M EGFR G796R EGFR L858R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15793,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of EAI045 and Erbitux (cetuximab) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31214,
                "profileName": "EGFR T790M EGFR G796R EGFR L858R"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15781,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) did not inhibit Egfr phosphorylation and proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31214,
                "profileName": "EGFR T790M EGFR G796R EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15779,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR L792HG796R in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31214,
                "profileName": "EGFR T790M EGFR G796R EGFR L858R"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15787,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 did not inhibit proliferation of transformed cells expressing EGFR L858R and T790M in cis with EGFR G796R in culture (PMID: 29857056).",
            "molecularProfile": {
                "id": 31214,
                "profileName": "EGFR T790M EGFR G796R EGFR L858R"
            },
            "therapy": {
                "id": 4520,
                "therapyName": "EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15797,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, EGFR G796R was identified in 0.59% (2/340) of lung adenocarcinoma patients receiving Tagrisso (osimertinib), and 1 of the 2 patients also had EGFR T790M in cis, consistent with cell culture study and structural modeling that supports a role of EGFR G796R in cis with T790M in conferring resistance to Tagrisso (osimertinib) (PMID: 29857056).",
            "molecularProfile": {
                "id": 31221,
                "profileName": "EGFR T790M EGFR G796R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13806,
                    "pubMedId": 29857056,
                    "title": "EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29857056"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31212,
            "profileName": "EGFR G796R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31214,
            "profileName": "EGFR T790M EGFR G796R EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31221,
            "profileName": "EGFR T790M EGFR G796R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 177982,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181395G>C",
            "cDna": "c.2386G>C",
            "protein": "p.G796R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}